According to data and analytics company, GlobalData, pharmaceutical sales within the age-related macular degeneration (AMD) markets will soar to $11.5 billion by the year 2026.
Eye treatment
The report, ‘PharmaPoint: Age-Related Macular Degeneration’, reveals that the growth in the AMD market will be driven by new therapies set to enter the sector and a global ageing society that will lead to an increase in the numbers of elderly people developing AMD.